Fox Run Management L.L.C. Acquires 6,906 Shares of BioNTech SE Sponsored ADR $BNTX

Fox Run Management L.L.C. boosted its stake in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 242.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,750 shares of the company’s stock after buying an additional 6,906 shares during the period. Fox Run Management L.L.C.’s holdings in BioNTech were worth $962,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in BNTX. BNP Paribas Financial Markets raised its position in shares of BioNTech by 6.7% in the 2nd quarter. BNP Paribas Financial Markets now owns 1,275,475 shares of the company’s stock worth $135,800,000 after acquiring an additional 80,005 shares in the last quarter. Bank of New York Mellon Corp grew its stake in BioNTech by 58.8% in the second quarter. Bank of New York Mellon Corp now owns 1,108,719 shares of the company’s stock valued at $118,045,000 after purchasing an additional 410,351 shares during the last quarter. Dodge & Cox bought a new position in BioNTech in the second quarter worth about $93,421,000. Franklin Resources Inc. lifted its position in shares of BioNTech by 76.8% during the second quarter. Franklin Resources Inc. now owns 751,998 shares of the company’s stock valued at $80,065,000 after buying an additional 326,556 shares during the last quarter. Finally, Invesco Ltd. lifted its position in shares of BioNTech by 5.6% during the second quarter. Invesco Ltd. now owns 681,100 shares of the company’s stock valued at $72,517,000 after buying an additional 35,958 shares during the last quarter. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

BioNTech Price Performance

Shares of BNTX opened at $108.80 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.12 and a quick ratio of 7.02. The company’s fifty day moving average price is $105.59 and its 200-day moving average price is $103.52. BioNTech SE Sponsored ADR has a 1-year low of $81.20 and a 1-year high of $124.00. The firm has a market capitalization of $24.50 billion, a PE ratio of -41.37 and a beta of 1.49.

Wall Street Analysts Forecast Growth

BNTX has been the subject of several recent analyst reports. TD Cowen reiterated a “hold” rating on shares of BioNTech in a research note on Monday, November 3rd. Leerink Partners downgraded BioNTech from an “outperform” rating to a “market perform” rating and set a $113.00 price target on the stock. in a research report on Monday, February 2nd. Jefferies Financial Group reiterated a “buy” rating and set a $151.00 price objective on shares of BioNTech in a report on Wednesday, December 3rd. HC Wainwright reissued a “buy” rating and issued a $140.00 price objective on shares of BioNTech in a research report on Thursday, December 11th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $134.00 target price on shares of BioNTech in a research report on Monday, November 3rd. Eleven analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $140.10.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.